Welcome to medications.com
Sosei Announces Start of AD 923 Phase III Studies in Europe - FOXBusiness
... AD 923 against an active comparator (morphine sulphate immediate release (MSIR)) for the treatment of breakthrough pain in patients with malignancies. ...
http://www.foxbusiness.com/articl... |
Posted: Tue Feb 12 14:23:09 -0500 2008
MSIR RSS FeedFrequently Reported Side Effects of MSIR
© 2002-2007, Skylabs Inc. |
About Us |
Disclaimer/Terms of Use |
Advertise |
Contact Us |
Site Map |
Developed by:
W3matter.com
